U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium

Atracurium is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. It is used, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Most adverse reactions were suggestive of histamine release. Common side effects include flushing of the skin and low blood pressure. Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

CNS Activity

Originator

Approval Year

1983
53
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
 169.5 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8360
ATRACURIUM BESYLATE

Approved Use

Atracurium Besylate Injection, USP is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Launch Date

8.6918398E11
PubMed

PubMed

TitleDatePubMed
[Relaxation and the electromyographic identification of the recurrent laryngeal nerve].
2002 Sep
[Interaction of donepezil and muscular blockers in Alzheimer's disease].
2003 Feb
[Establishment of a hypothermic dog model to investigate airway rewarming].
2006 Aug
A prospective randomized double blind study to evaluate the effect of infusion of amino Acid enriched solution on recovery from neuromuscular blockade.
2009 Jun
Modulation of temporal precision in thalamic population responses to natural visual stimuli.
2010
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Comparison between Culture Conditions Improving Growth and Differentiation of Blood and Bone Marrow Cells Committed to the Endothelial Cell Lineage.
2010 Feb 6
Cisatracurium in different doses versus atracurium during general anesthesia for abdominal surgery.
2010 Sep
Patents

Patents

DE 2655883
2
US 4179507
2

Sample Use Guides

In Vivo Use Guide
An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED95), given as an intravenous bolus injection, is the recommended initial dose for most patients. Maximum neuromuscular block achieved approximately 3 to 5 minutes after injection.
Route of Administration: Intravenous
In Vitro Use Guide
Exposure of isolated rat hepatocytes to atracurium produced cellular damage evidenced by extrusion of an intracellular enzyme, lactate dehydrogenase (LDH), into the incubation medium. Leakage of LDH was directly related to the concentration of atracurium in the medium (250 to 800 microM). When atracurium was added to the medium and the medium immediately added to hepatocytes, the leakage of LDH increased as the concentration of atracurium increased (P < 0.001 for the comparison with cells not exposed to atracurium).
Substance Class Mixture
Created
by admin
on Wed Jul 05 23:48:54 UTC 2023
Edited
by admin
on Wed Jul 05 23:48:54 UTC 2023
Record UNII
2GQ1IRY63P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATRACURIUM
VANDF   WHO-DD  
Common Name English
ATRACURIUM CATION
Common Name English
ATRACURIUM [VANDF]
Common Name English
2-(2-CARBOXYETHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-VERATRYLISOQUINOLINIUM, PENTAMETHYLENE ESTER
Common Name English
ISOQUINOLINIUM, 2,2'-(1,5-PENTANEDIYLBIS(OXY(3-OXO-3,1-PROPANEDIYL)))BIS(1-((3,4-DIMETHOXYPHENYL)METHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL
Common Name English
ATRACURIUM ION
Common Name English
Atracurium [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175720
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 20
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
WHO-VATC QM03AC04
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
NCI_THESAURUS C66886
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
WHO-ATC M03AC04
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
NDF-RT N0000175732
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
Code System Code Type Description
FDA UNII
2GQ1IRY63P
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
MESH
D001279
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
CHEBI
2914
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
NCI_THESAURUS
C76068
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
LACTMED
Atracurium
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
EVMPD
SUB00618MIG
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID9043726
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
CAS
64228-79-1
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
DRUG CENTRAL
259
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
DAILYMED
2GQ1IRY63P
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
DRUG BANK
DB00732
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
RXCUI
1218
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY RxNorm
WIKIPEDIA
ATRACURIUM
Created by admin on Wed Jul 05 23:48:54 UTC 2023 , Edited by admin on Wed Jul 05 23:48:54 UTC 2023
PRIMARY
All of the following components must be present:
Structure of ATRACURIUM, (1R,2R,1'R,2'S)-(±)-
Structure of ATRACURIUM, (1S,2R,1'S,2'R)-(±)-
Structure of ATRACURIUM, (1R,1'R,2R,2'R)-(±)-
Structure of ATRACURIUM, (1R,2S,1'S,2'R)-
Structure of ATRACURIUM, (1R,2R,1'S,2'S)-
Structure of ATRACURIUM, (1R,2R,1'S,2'R)-(±)-
Related Record Type Details
ATRACURIUM BESYLATE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
ATRACURIUM
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Definition References
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966